Senti Biosciences, Inc. (SNTI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Senti Biosciences, Inc. (SNTI) trades at $0.436 with AI Score 16/100 (Grade F). Senti Biosciences, Inc. is a gene circuit company focused on developing cell and gene therapies engineered with synthetic biology. Market cap: $13.6M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for SNTI: SNTI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNTI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SNTI: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Senti Biosciences, Inc. (SNTI) Healthcare & Pipeline Overview
Senti Biosciences is a clinical-stage biotechnology company pioneering gene circuit technology to develop next-generation cell and gene therapies. Their synthetic biology platform, leveraging CAR-NK cells, targets challenging oncology indications like AML, HCC, and CRC, positioning them within the competitive and rapidly evolving gene therapy landscape.
What Is the Investment Thesis for SNTI?
Senti Biosciences presents a high-risk, high-reward investment opportunity within the gene therapy space. The company's gene circuit technology and CAR-NK cell platform offer a novel approach to targeting complex diseases, particularly in oncology. Key value drivers include the successful advancement of SENTI-202, SENTI-301, and SENTI-401 through clinical trials. The company's ability to secure partnerships and funding will be critical for long-term success. With a market cap of $13.6M and negative profit and gross margins, the company's financial performance hinges on achieving clinical milestones and commercializing its therapies. Upcoming clinical trial results and regulatory approvals represent significant catalysts. However, the company faces potential risks related to clinical trial outcomes, regulatory hurdles, and competition from established players in the gene therapy market.
Based on FMP financials and quantitative analysis
SNTI Key Highlights
Market Cap of $13.6M reflects the company's early stage and speculative nature.
- Negative Profit Margin of -279263.6% indicates substantial ongoing investment in research and development.
- Negative Gross Margin of -14777.3% highlights the current lack of revenue generation from commercial products.
- Beta of 2.12 suggests high volatility compared to the overall market.
- Focus on CAR-NK cell therapies positions the company in a rapidly evolving area of cancer treatment.
Who Are SNTI's Competitors?
SNTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| EDIT Editas Medicine, Inc. | $2.94 | -9.54% | $451M | — |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.7M | 67 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNTI's Key Strengths?
Novel gene circuit technology.
- Focus on CAR-NK cell therapies.
- Pipeline of therapies targeting specific oncology indications.
- Experienced leadership team.
What Are SNTI's Weaknesses?
Early-stage company with limited revenue.
- High research and development costs.
- Dependence on clinical trial success.
- Competition from established players.
What Could Drive SNTI Stock Higher?
Clinical trial results for SENTI-202 in AML.
- Clinical trial results for SENTI-301 in HCC.
- Preclinical data for SENTI-401 in CRC.
- Advancement of gene circuit technology platform.
- Strategic partnerships and collaborations.
What Are the Key Risks for SNTI?
Financial-distress signal — its Altman Z-Score of -20.87 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other therapies.
- High research and development costs.
- Dependence on securing additional funding.
What Are the Growth Opportunities for SNTI?
- Advancement of SENTI-202 for AML: The successful development and commercialization of SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy, represents a significant growth opportunity. Clinical trial results and regulatory approvals will be key milestones in the coming years.
- Development of SENTI-301 for HCC: SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC), offers another substantial growth avenue. The HCC market is also projected to grow significantly, and SENTI-301's unique approach could address unmet needs in this area. Clinical trials and regulatory approvals are critical steps for realizing this opportunity.
- Expansion of the Pipeline with SENTI-401 for CRC: The development of SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells, presents a further growth opportunity. The CRC market is substantial, and SENTI-401's potential to improve treatment outcomes could drive adoption. Preclinical and clinical data will be essential for advancing this program.
- Strategic Partnerships and Collaborations: Senti Biosciences can leverage strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its therapies. These collaborations can provide access to funding, expertise, and resources, enhancing the company's growth prospects. Securing such partnerships will be crucial for long-term success.
- Expansion into New Therapeutic Areas: While currently focused on oncology, Senti Biosciences' gene circuit technology has the potential to be applied to other therapeutic areas, such as autoimmune diseases or infectious diseases. Expanding into these new areas could diversify the company's pipeline and create additional growth opportunities. Research and development efforts will be necessary to explore these possibilities.
What Are SNTI's Competitive Advantages?
- Proprietary gene circuit technology.
- Expertise in CAR-NK cell therapy development.
- Pipeline of novel therapies targeting specific oncology indications.
- Intellectual property protection through patents.
What Does SNTI Do?
Senti Biosciences, Inc., founded in 2016 and based in South San Francisco, California, operates as a gene circuit company focused on developing cell and gene therapies. The company engineers these therapies with gene circuits designed to reprogram cells using biological logic, enabling them to sense inputs, compute decisions, and respond to specific cellular environments. Senti Biosciences' synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target oncology indications, including liquid and solid tumors. Their lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing healthy bone marrow. Another key program is SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). The company is also developing SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while preserving healthy cells. Senti Biosciences aims to improve patient outcomes by creating more precise and effective cell and gene therapies.
What Products and Services Does SNTI Offer?
- Develops cell and gene therapies engineered with gene circuits.
- Utilizes synthetic biology to reprogram cells with biological logic.
- Focuses on off-the-shelf CAR-NK cell therapies.
- Targets liquid and solid tumor oncology indications.
- Develops SENTI-202 for acute myeloid leukemia (AML).
- Develops SENTI-301 for hepatocellular carcinoma (HCC).
- Develops SENTI-401 for colorectal cancer (CRC).
How Does SNTI Make Money?
- Develops and patents gene circuit technology.
- Conducts preclinical and clinical research to validate therapies.
- Seeks regulatory approval for its therapies.
- Aims to commercialize its therapies through partnerships or direct sales.
What Industry Does SNTI Operate In?
Senti Biosciences operates within the biotechnology industry, specifically in the rapidly evolving field of gene and cell therapy. The market for gene therapies is projected to experience substantial growth, driven by advancements in technology and increasing prevalence of genetic disorders and cancer. The competitive landscape includes established pharmaceutical companies and specialized biotech firms. Senti Biosciences differentiates itself through its gene circuit technology and focus on CAR-NK cell therapies, targeting specific oncology indications. The company's success depends on navigating regulatory hurdles, demonstrating clinical efficacy, and securing market access in a competitive environment.
Who Are SNTI's Key Customers?
- Hospitals and cancer centers.
- Oncologists and hematologists.
- Patients with AML, HCC, and CRC.
- Pharmaceutical companies (potential partners).
Company Profile
Senti Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Timothy K. Lu. SNTI has traded publicly since 2021.
How Senti Biosciences, Inc. Is Valued
Senti Biosciences, Inc. carries a market capitalization of $13.6M, placing it in the micro-cap category. Relative to its peer group, SNTI's quantitative score of 16/100 is below the peer average of 66/100.
Financial Health
Senti Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.87 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Senti Biosciences, Inc. revenue of about $39K for fiscal 2026, with EPS near $-1.04.
SNTI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel gene circuit technology.
- Focus on CAR-NK cell therapies.
- Pipeline of therapies targeting specific oncology indications.
- Experienced leadership team.
Bear Case
- Early-stage company with limited revenue.
- High research and development costs.
- Dependence on clinical trial success.
- Competition from established players.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SNTI Latest News
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Jul 16, 2026
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Jul 15, 2026
SNTI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNTI.
Price Targets
Wall Street price target analysis for SNTI.
SNTI MoonshotScore
What does this score mean?
The MoonshotScore rates SNTI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Timothy K. Lu
CEO
Timothy K. Lu is the CEO of Senti Biosciences. He is also a Professor at MIT in Electrical Engineering and Computer Science and Biological Engineering. His research focuses on synthetic biology, with applications in medicine and biotechnology. He has co-authored numerous scientific publications and holds several patents in the field. Dr. Lu is also a co-founder of several biotech companies.
Track Record: As CEO of Senti Biosciences, Timothy K. Lu has led the company's efforts to develop its gene circuit technology and CAR-NK cell therapies. He has overseen the advancement of the company's pipeline through preclinical and clinical development. His leadership has been instrumental in securing funding and establishing strategic partnerships. However, the company's long-term success remains dependent on achieving clinical milestones and commercializing its therapies.
SNTI Healthcare Stock FAQ
What does the AI Score mean for SNTI?
SNTI holds an AI Score of 16/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Senti Biosciences, Inc. is a gene circuit company focused on developing cell and gene therapies engineered with synthetic biology. Their platform utilizes CAR-NK cells to target challenging …
What does Senti Biosciences, Inc. do?
Senti Biosciences is a biotechnology company pioneering gene circuit technology to develop cell and gene therapies. They engineer cells with synthetic DNA circuits that enable them to sense, compute, and respond to specific disease environments. Their primary focus is on developing CAR-NK cell therapies for oncology, including treatments for AML, HCC, and CRC. The company's approach aims to create more precise and effective therapies with improved safety profiles.
What do analysts say about SNTI stock?
Given Senti Biosciences' market cap of $13.6M and focus on early-stage clinical development, analyst coverage may be limited. The stock is likely viewed as a high-risk, high-reward investment, with significant potential upside if the company's therapies prove successful in clinical trials. Key valuation metrics include the potential market size for its therapies and the likelihood of regulatory approval.
What are the main risks for SNTI?
Senti Biosciences faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from other therapies. The company's high research and development costs and dependence on securing additional funding also pose significant risks. Additionally, the company's reliance on its gene circuit technology and CAR-NK cell platform makes it vulnerable to technological advancements by competitors. Investors should carefully evaluate these risks before investing in SNTI.
What are the key factors to evaluate for SNTI?
Senti Biosciences, Inc. (SNTI) holds an AI score of 16/100 (low). Senti Biosciences presents a high-risk, high-reward investment opportunity within the gene therapy space. Not financial advice.
How frequently does SNTI data refresh on this page?
SNTI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNTI's recent stock price performance?
Senti Biosciences, Inc. (SNTI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel gene circuit technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNTI overvalued or undervalued right now?
Senti Biosciences, Inc. (SNTI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SNTI before investing?
Before investing in Senti Biosciences, Inc. (SNTI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is limited and may not be fully comprehensive.